Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions is set to benefit from the opening of the Aby J. Mathew Center for Biopreservation Excellence, showcasing their full product portfolio and supporting research efforts for new cryopreservation products. With an impressive revenue growth of 31% in Q3 and strong market share in their biopreservation media, the recent divestment of their evo business will further streamline the company and allow for continued growth and margin expansion. BioLife's FY2025 revenue guidance and expected reduction in net loss further solidifies our positive outlook on the company's financials.

Bears say

BioLife Solutions is currently in a strong cash position, with $98.4 million in cash and marketable securities as of September 2025. However, the company's cash flows from operating activities were only $6.1 million in 3Q25 and its adjusted EBITDA was approximately $7.8 million, suggesting that its profitability may be limited in the short term. Additionally, while the company has a solid revenue stream from its Cell Processing segment, there may be potential risks and challenges in the rapidly evolving field of cell and gene therapy that could impact its growth and future earnings potential.

BioLife Solutions (BLFS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.